|
[1]
|
WHO position paper on hepatitis A vaccines - June 2012. Wkly Epidemiol Rec 2012;87(28-29):261-76. https://pubmed.ncbi.nlm.nih.gov/22905367/.https://pubmed.ncbi.nlm.nih.gov/22905367/ |
|
[2]
|
Tang YW, Wang JX, Xu ZY, Guo YF, Qian WH, Xu JX. A serologically confirmed, case-control study, of a large outbreak of hepatitis A in China, associated with consumption of clams. Epidemiol Infect 1991;107(3):651 − 7. http://dx.doi.org/10.1017/s0950268800049347CrossRef
|
|
[3]
|
Barzaga NG. Hepatitis A shifting epidemiology in South-East Asia and China. Vaccine 2000;18(S1):S61 − 4. http://dx.doi.org/10.1016/s0264-410x(99)00467-3CrossRef
|
|
[4]
|
Cui FQ, Hadler SC, Zheng H, Wang FZ, Wu ZH, Hu YS, et al. Hepatitis A surveillance and vaccine use in China from 1990 through 2007. J Epidemiol 2009;19(4):189 − 95. http://dx.doi.org/10.2188/jea.je20080087CrossRef
|
|
[5]
|
Sun XJ, Wang FZ, Zheng H, Miao N, Yuan QL, Cui FQ, et al. The impact of expanded program on immunization with live attenuated and inactivated Hepatitis A vaccines in China, 2004-2016. Vaccine 2018;36(10):1279 − 84. http://dx.doi.org/10.1016/j.vaccine.2018.01.043CrossRef
|
|
[6]
|
Levine H, Kopel E, Anis E, Givon-Lavi N, Dagan R. The impact of a national routine immunisation programme initiated in 1999 on Hepatitis A incidence in Israel, 1993 to 2012. Euro Surveill 2015;20(7):3 − 10. http://dx.doi.org/10.2807/1560-7917.es2015.20.7.21040CrossRef
|
|
[7]
|
Murphy TV, Denniston MM, Hill HA, McDonald M, Klevens MR, Elam-Evans LD, et al. Progress toward eliminating hepatitis a disease in the United States. MMWR Suppl 2016;65(1):29 − 41. http://dx.doi.org/10.15585/mmwr.su6501a6CrossRef
|
|
[8]
|
Wang FZ, Sun XJ, Wang F, Zheng H, Jia ZY, Zhang GM, et al. Changing epidemiology of Hepatitis A in China: evidence from three national serological surveys and the National Notifiable Disease Reporting System. Hepatology 2020. http://dx.doi.org/10.1002/hep.31429CrossRef
|
|
[9]
|
Sun XJ, Zhang GM, Zhou RJ, Zheng H, Miao N, Yin ZD, et al. Changes in the epidemiology of hepatitis A in three socio-economic regions of China, 1990-2017. Infect Dis Pov 2019;8(1):80. http://dx.doi.org/10.1186/s40249-019-0591-zCrossRef
|
|
[10]
|
Wang H, Gao P, Chen WX, Bai S, Lv M, Ji WY, et al. Changing epidemiological characteristics of Hepatitis A and warning of Anti-HAV immunity in Beijing, China: a comparison of prevalence from 1990 to 2017. Hum Vacc Immun 2019;15(2):420 − 5. http://dx.doi.org/10.1080/21645515.2018.1529128CrossRef
|
|
[11]
|
Yan BY, Lv JJ, Liu JY, Feng Y, Wu WL, Xu AQ, et al. Changes in seroprevalence of hepatitis A after the implementation of universal childhood vaccination in Shandong Province, China: a comparison between 2006 and 2014. Int J Infect Dis 2019;82:129 − 34. http://dx.doi.org/10.1016/j.ijid.2019.03.005CrossRef
|
|
[12]
|
Yan HK, Guan J, Wushouer F. Hepatitis a vaccination and antibody levels among children aged 0-6 years in Xinjiang Uygur Autonomous Region, 2013. Chin J Vacc Immun. 2018;24(1):27-31. http://d.wanfangdata.com.cn/periodical/zgjhmy201801007. (In Chinese). http://d.wanfangdata.com.cn/periodical/zgjhmy201801007 |